Bristol Myers Squibb announced it will present new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain. The presentations will feature significant updates on Camzyos (mavacamten) for hypertrophic cardiomyopathy patients and data from the BMS-Pfizer Alliance on Eliquis (apixaban).
"With a 70-year legacy in cardiovascular medicine, we are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM," said Roland Chen, MD, senior vice president, drug development, Immunology and Cardiovascular Medicines, Bristol Myers Squibb. "Camzyos is the first and only available cardiac myosin inhibitor supported by robust long-term extension and real-world effectiveness data in patients with oHCM, with clinical studies demonstrating symptom relief as well as improvements in functional capacity and cardiac structure, both with and without background therapy."
Key Clinical Presentations
The company will deliver three major oral presentations highlighting the expanding evidence base for Camzyos. The first presentation will showcase real-world outcomes from COLLIGO-HCM, a global observational study reflecting diverse patient populations across five countries: the United States, Canada, the United Kingdom, Australia, and Israel. This study provides crucial real-world evidence supporting Camzyos' effectiveness in treating symptomatic obstructive hypertrophic cardiomyopathy.
A second oral presentation will spotlight the efficacy and safety of Camzyos monotherapy based on a pooled analysis of four Phase 3 studies. This comprehensive analysis reinforces the drug's therapeutic benefits when used as a standalone treatment for patients with obstructive HCM.
Breakthrough Non-Obstructive HCM Data
Perhaps most significantly, Bristol Myers Squibb will present late-breaking topline results from ODYSSEY-HCM, a Phase 3 randomized, double-blind, placebo-controlled trial involving 580 adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM). This represents the largest and longest-duration study completed to date in this patient population, potentially expanding Camzyos' therapeutic reach beyond obstructive disease.
Camzyos: First-in-Class Cardiac Myosin Inhibitor
Camzyos (mavacamten) stands as the first and only cardiac myosin inhibitor approved in the U.S. for treating adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. The drug has received regulatory approvals in more than 50 countries and regions across five continents.
As a selective, reversible, allosteric inhibitor of cardiac myosin, Camzyos modulates the number of myosin heads that can enter "on actin" (power-generating) states, reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. This mechanism addresses the excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state that are mechanistic hallmarks of HCM.
In obstructive HCM patients, myosin inhibition with Camzyos reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures. These cardiac effects translate to symptom improvement and enhanced ability to be active in symptomatic patients.
Safety Profile and Monitoring Requirements
Camzyos carries a boxed warning for risk of heart failure due to its ability to reduce left ventricular ejection fraction (LVEF) and cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment, with initiation not recommended in patients with LVEF <55%. Treatment must be interrupted if LVEF falls below 50% at any visit or if patients experience heart failure symptoms.
In the EXPLORER-HCM trial, adverse reactions occurring in more than 5% of patients and more commonly in the Camzyos group than placebo were dizziness (27% vs 18%) and syncope (6% vs 2%). Mean absolute change from baseline in LVEF was -4% in the Camzyos group compared to 0% in the placebo group over the 30-week treatment period, though LVEF returned to baseline levels following an 8-week interruption.
Due to the risk of heart failure, Camzyos is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CAMZYOS REMS PROGRAM, requiring certified prescribers, enrolled patients, and certified pharmacies.
Eliquis Data Presentations
The ESC Congress will also feature data on behalf of the BMS-Pfizer Alliance on Eliquis (apixaban), an oral selective Factor Xa inhibitor approved for multiple cardiovascular indications. Eliquis is indicated to reduce stroke and systemic embolism risk in adult patients with non-valvular atrial fibrillation, for deep vein thrombosis prophylaxis following hip or knee replacement surgery, and for treating DVT and pulmonary embolism in both adult and pediatric patients.
